カテゴリー： Allied Market Research, 世界, 医療/バイオ

核酸治療薬の世界市場2021-2031：機会分析・産業予測

◆英語タイトル：Nucleic Acid Therapeutics Market By Products (Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], Others), By Application  (Monogenetic disorders, Multi-genetic disorders), By End User (Hospitals and Clinics, Academic and Research Institutes): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが発行した調査報告書（ALD22NV0147）◆商品コード：ALD22NV0147
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2022年7月
◆ページ数：315
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single UserUSD5,769 ⇒換算￥796,122見積依頼/購入/質問フォーム
5 UserUSD6,630 ⇒換算￥914,940見積依頼/購入/質問フォーム
Enterprise UserUSD10,500 ⇒換算￥1,449,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Allied Market Research社の本調査資料では、世界核酸治療薬市場を調査対象とし、イントロダクション、エグゼクティブサマリー、市場概要、製品別（アンチセンスオリゴヌクレオチド（ASO）＆DNAアプタマー、RNA干渉（RNAi）＆短鎖干渉RNA（siRNA）、その他）分析、用途別（単一遺伝子疾患、複数遺伝子疾患）分析、エンドユーザー別（病院＆クリニック、学術＆研究機関）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況などについて以下の構成でまとめております。なお、参入企業情報として、Agilent Technologies、Alnylam Pharmaceuticals、Arbutus Biopharma、Arrrowhead、Benitec Biopharma、Caperna、Copernicus、Genzyme Sanofi、Ionis Pharmaceuticals、Merck、Novartis A.G、PYC Therapeutics Limited、Protagonist Therapeutics、Qaigen NV、Sarpeta Therapeuticsなどが含まれております。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の核酸治療薬市場規模：製品別
- アンチセンスオリゴヌクレオチド（ASO）＆DNAアプタマーの市場規模
- RNA干渉（RNAi）＆短鎖干渉RNA（siRNA）の市場規模
- その他製品の市場規模
・世界の核酸治療薬市場規模：用途別
- 単一遺伝子疾患における市場規模
- 複数遺伝子疾患における市場規模
・世界の核酸治療薬市場規模：エンドユーザー別
- 病院＆クリニックにおける市場規模
- 学術＆研究機関における市場規模
・世界の核酸治療薬市場規模：地域別
- 北米の核酸治療薬市場規模
- ヨーロッパの核酸治療薬市場規模
- アジア太平洋の核酸治療薬市場規模
- 中南米・中東・アフリカの核酸治療薬市場規模
・企業状況
・企業情報
❖ レポートの概要 ❖

Nucleic acids are chemical substances and carry genetic information of the cell. The three types of nucleic acids are deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and artificial nucleic acid.
Watson-Crick base pairing recognizes endogenous nucleic acids in a sequence-specific manner, mediating the shared mode of action of all nucleic acids. The nucleic acid-based therapies are widely used to treat various chronic diseases. Nucleic acid shows the significant therapeutic result in chronic diseases, such as cancer, tumor, diabetes, tuberculosis, and human immunodeficiency virus (HIV). For instance, in recent years, the global nucleic acid therapeutics has gained extensive attention. Moreover, the increasing chronic illnesses and the search for cure of chronic illnesses is an international concern, therefore nucleic acid therapeutics is observing increased attention.
The nucleic acid therapeutics shows long lasting effects through gene editing, gene inhibition, gene addition or gene replacement. Furthermore, the increase in chronic disease prevalence and patients seeking treatment of nucleic acid therapies help in the global nucleic acid therapeutics market growth. Nucleic acid therapeutics shows the long lasting and curative effects. The key drivers for the growth of the global nucleic acid therapeutics market are increasing chronic illness and immensely developing novel treatments of nucleic acids. The high cost of research and development and expensive treatments and technologies are some major elements restraining the market growth. High product demand and growing concentration of pharmaceutical companies on the development of treatment for nucleic acid therapeutics are additional factors that are driving the nucleic acid therapeutics market growth. The lack of treatment alternatives for cancer, muscular dystrophy, and human immunodeficiency virus (HIV) is the important reason for global nucleic acid therapeutics market expansion. The nucleic acid therapeutics market will revamp on approval of the developing therapies for amyloidosis by using antisense oligonucleotide to lower transthyretin (TTR) levels and dose escalation to investigate safety of ISTH0036 in glaucoma undergoing trabeculectomy patients. For instance, there are various therapies under pipeline, which are expected to serve the demand for  nucleic acid therapies globally and contribute to the market growth.
The nucleic acid therapeutics is segmented on the basis of products, application, end user, and region. Based on the products, the market is bifurcated into anti-sense oligonucleotides (ASOS) and DNA aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and others. The others segment is further classified into antagomir and RNA sponge and locked nucleic acid. By application, the market is fragmented into monogenetic disorders and multi-genetic disorders. By end user, the market is segmented into hospitals & clinics and academic & research institutes.
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players that operate in the global nucleic acid therapeutics market are Agilent Technologies Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Benetic Biopharma, Inc., Caperna Inc. [Moderna], Copernicus Therapeutics, Genzyme (Sanofi), Ionis Pharmaceuticals, MERCK KGAA, Novartis AG, Phylogica, Protagonist Therapeutics, QIAGEN N.V., Sarepta Therapeutics, Silence Therapeutics plc., and Thermo Fisher Scientific Inc.

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid therapeutics market analysis from 2021 to 2031 to identify the prevailing nucleic acid therapeutics market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the nucleic acid therapeutics market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global nucleic acid therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Products
● Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
● RNA interference [RNAi] and short interfering RNAs [siRNAs]
● Others

By Application 
● Monogenetic disorders
● Multi-genetic disorders

By End User
● Hospitals and Clinics
● Academic and Research Institutes

By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ Australia
○ India
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA

● Key Market Players
○ Agilent Technologies
○ Alnylam Pharmaceuticals
○ Arbutus Biopharma
○ Arrrowhead
○ Benitec Biopharma
○ Caperna
○ Copernicus
○ Genzyme Sanofi
○ Ionis Pharmaceuticals
○ Merck
○ Novartis A.G
○ PYC Therapeutics Limited
○ Protagonist Therapeutics
○ Qaigen NV
○ Sarpeta Therapeutics
○ Silence Therapeutics
○ Thermo Fisher Scientific
○ Wavelifesciences

❖ レポートの目次 ❖

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS
4.1 Overview
4.1.1 Market size and forecast
4.2 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 RNA interference [RNAi] and short interfering RNAs [siRNAs] 4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION 
5.1 Overview
5.1.1 Market size and forecast
5.2 Monogenetic disorders
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Multi-genetic disorders
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: NUCLEIC ACID THERAPEUTICS MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals and Clinics
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Academic and Research Institutes
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: NUCLEIC ACID THERAPEUTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Products
7.2.3 North America Market size and forecast, by Application 
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Products
7.2.5.1.2 Market size and forecast, by Application 
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Products
7.2.5.2.2 Market size and forecast, by Application 
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Products
7.2.5.3.2 Market size and forecast, by Application 
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Products
7.3.3 Europe Market size and forecast, by Application 
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Products
7.3.5.1.2 Market size and forecast, by Application 
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Products
7.3.5.2.2 Market size and forecast, by Application 
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Products
7.3.5.3.2 Market size and forecast, by Application 
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Products
7.3.5.4.2 Market size and forecast, by Application 
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Products
7.3.5.5.2 Market size and forecast, by Application 
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Products
7.3.5.6.2 Market size and forecast, by Application 
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Products
7.4.3 Asia-Pacific Market size and forecast, by Application 
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Products
7.4.5.1.2 Market size and forecast, by Application 
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Products
7.4.5.2.2 Market size and forecast, by Application 
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Products
7.4.5.3.2 Market size and forecast, by Application 
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Products
7.4.5.4.2 Market size and forecast, by Application 
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Products
7.4.5.5.2 Market size and forecast, by Application 
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Products
7.4.5.6.2 Market size and forecast, by Application 
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Products
7.5.3 LAMEA Market size and forecast, by Application 
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Products
7.5.5.1.2 Market size and forecast, by Application 
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Products
7.5.5.2.2 Market size and forecast, by Application 
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Products
7.5.5.3.2 Market size and forecast, by Application 
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Products
7.5.5.4.2 Market size and forecast, by Application 
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Agilent Technologies
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Alnylam Pharmaceuticals
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Arbutus Biopharma
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Arrrowhead
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Benitec Biopharma
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Caperna
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Copernicus
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Genzyme Sanofi
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Ionis Pharmaceuticals
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Merck
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Novartis A.G
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 PYC Therapeutics Limited
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Protagonist Therapeutics
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Qaigen NV
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Sarpeta Therapeutics
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Silence Therapeutics
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Thermo Fisher Scientific
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
9.18 Wavelifesciences
9.18.1 Company overview
9.18.2 Company snapshot
9.18.3 Operating business segments
9.18.4 Product portfolio
9.18.5 Business performance
9.18.6 Key strategic moves and developments



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 核酸治療薬の世界市場2021-2031：機会分析・産業予測(Nucleic Acid Therapeutics Market By Products (Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], Others), By Application  (Monogenetic disorders, Multi-genetic disorders), By End User (Hospitals and Clinics, Academic and Research Institutes): Global Opportunity Analysis and Industry Forecast, 2021-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • フェイシャルエステティックの世界市場2021-2031：機会分析・産業予測
    ALD22NV0272 / Allied Market Research / 2022年7月 / Allied Market Research社の本調査資料では、世界のフェイシャルエステティック市場規模が2021年6,234.5百万ドルから2031年25,764.5百万ドルに達し、2022年から2031年まで年平均15.5％成長すると予測しています。当書は、フェイシャルエステティックの世界市場を調査対象とし、イントロダクション、エグゼクティブサマリー、市場概要、製品別（ダーマフィラー、ボツリヌス毒素、マイクロダーマブレーション、ケミカルピーリング、その他）分析、用途別（フェイスライン修正、傷跡治療、リップアップ、ボリューム・膨らみ回復、その他）分析、エンドユーザー別（専門医院、病院、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、企業状況などについて以下の構成でまとめております。なお、参入企業情報として、Abbvie...
  • 外科用ドリルの世界市場2021-2031：機会分析・産業予測
    ALD22NV0091 / Allied Market Research / 2022年7月 / Allied Market Research社の本調査資料では、世界の外科用ドリル市場規模が2021年983.55百万ドルから2031年1,516.35百万ドルに達し、2022年から2031年まで年平均4.4％成長すると予測しています。当書は、外科用ドリルの世界市場を調査対象とし、イントロダクション、エグゼクティブサマリー、市場概要、製品別（機器、付属品）分析、用途別（整形外科、神経外科、耳鼻咽喉科、歯科外科、その他）分析、エンドユーザー別（病院、クリニック、外来外科センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況などについて以下の構成でまとめております。なお、参入企業情報として、Adeor...
  • 体脂肪測定の世界市場2021-2031：機会分析・産業予測
    ALD22NV0205 / Allied Market Research / 2022年7月 / Allied Market Research社の本調査資料では、世界の体脂肪測定市場規模が2021年395.13百万ドルから2031年765百万ドルに達し、2022年から2031年まで年平均6.8％成長すると予測しています。当書は、体脂肪測定の世界市場を調査対象とし、イントロダクション、エグゼクティブサマリー、市場概要、製品別（キャリパー、体重計、その他）分析、技術別（生体インピーダンス分析、空気変位式容積脈波法、デュアルエミッションX線吸収法、静水圧式体重測定、その他）分析、エンドユーザー別（病院＆クリニック、フィットネスクラブ＆ウェルネスセンター、家庭用）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、企業状況などについて以下の構成でまとめております。なお、参入企業情報として、Accufitness,...
  • 放射線手術装置の世界市場2021-2031：機会分析・産業予測
    ALD22NV0056 / Allied Market Research / 2022年7月 / Allied Market Research社の本調査資料では、世界の放射線手術装置市場規模が2021年2,095.2百万ドルから2031年3,979.2百万ドルに達し、2022年から2031年まで年平均6.7％成長すると予測しています。当書は、放射線手術装置の世界市場を調査対象とし、イントロダクション、エグゼクティブサマリー、市場概要、種類別（リニア加速装置、陽子線治療、ガンマナイフ装置）分析、病態別（脳腫瘍、脊椎腫瘍）分析、エンドユーザー別（病院、学術＆研究機関）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況などについて以下の構成でまとめております。なお、参入企業情報として、ACCURAY...
  • 精液分析の世界市場2021-2031：機会分析・産業予測
    ALD22NV0074 / Allied Market Research / 2022年7月 / Allied Market Research社の本調査資料では、世界の精液分析市場規模が2021年955.47百万ドルから2031年1,486.78百万ドルに達し、2022年から2031年まで年平均4.5％成長すると予測しています。当書は、精液分析の世界市場を調査対象とし、イントロダクション、エグゼクティブサマリー、市場概要、製品別（精液分析装置、サンプル調製用遠心分離機、精液検査キット、使い捨て＆消耗品、ソフトウェア）分析、年齢層別（34歳以下、35～40歳、41歳以上）分析、エンドユーザー別（不妊治療センター、病院、診断研究所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況などについて以下の構成でまとめております。なお、参入企業情報として、Androfert、Arquimea...

    • ◆H&Iグローバルリサーチのお客様（例）◆